Seller record · Telehealth service

MEDVi

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published. The footer says the team gets updated reports on medication testing from its pharmacies, and no report is published.

At a glance

MEDViTelehealth service

7/8criteria passed

Price: Compounded semaglutide $179 the first month in a summer sale, then $299 a month
Sells: compounded GLP-1 injections, compounded GLP-1 dissolving tablets, and 3 more
FDA letters: 1 on file

Visit MEDVi See all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A telehealth weight loss service selling compounded GLP-1 injections and dissolving tablets, and prescribing the Wegovy pill, Wegovy and Zepbound for a membership fee plus the medication, with care from outside clinician networks after an online assessment. It names three partner pharmacies with addresses, and an FDA warning letter names the company.

Operating entity MEDVi, LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	MEDVi's GLP-1 storefront; MEDVi's home storefront
S2	Prescription gating	PASS	MEDVi's GLP-1 storefront; MEDVi's cancellation and refund policy on its home storefront
S3	Pharmacy identification	PASS	MEDVi's home storefront; MEDVi's GLP-1 storefront
S4	Compounding disclosure	PASS	MEDVi's home storefront; MEDVi's GLP-1 storefront
S5	Analytical documentation	FAIL	MEDVi's home storefront; MEDVi's GLP-1 storefront
S6	Business address	PASS	MEDVi's home storefront; MEDVi's terms and conditions on its home storefront; MEDVi's privacy policy on its home storefront
S7	Price disclosure	PASS	MEDVi's GLP-1 storefront
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSAn OpenLoop Health clinician meets each patient and decides whether to prescribe, and the footer says medical treatment is provided by affiliated professional corporations and OpenLoop Health.Source: MEDVi's GLP-1 storefront; MEDVi's home storefront.

S2PASSThe steps start with a quick online evaluation reviewed by licensed professionals before any prescription, the footer says the assessment screens out patients who do not qualify before checkout and a clinician then meets the patient, and the refund policy gives a full refund on medical disqualification.Source: MEDVi's GLP-1 storefront; MEDVi's cancellation and refund policy on its home storefront.

S3PASSThe footer names three partner pharmacies with addresses: Triad Rx, 26258 Pollard Rd, Daphne, AL 36526; RedRock Pharmacy, 1240 E 100 S #220, St. George, UT 84790; and Beaker Pharmacy & Compounding, 7810 Eldorado Pkwy STE 200, McKinney, TX 75072.Source: MEDVi's home storefront; MEDVi's GLP-1 storefront.

S4PASSThe home page states that compound medications are dispensed by state-licensed pharmacies but are not FDA approved, and the footer on every page says compounded GLP-1s are not FDA-approved or evaluated for safety, efficacy or quality.Source: MEDVi's home storefront; MEDVi's GLP-1 storefront.

S5FAILNo certificate of analysis or lot document is published. The footer says the team gets updated reports on medication testing from its pharmacies, and no report is published.Source: MEDVi's home storefront; MEDVi's GLP-1 storefront.

S6PASSMEDVi, LLC at 131 Continental Dr, Ste 305, Newark, DE 19713, printed in the footer of every page, in the terms and in the privacy policy.Source: MEDVi's home storefront; MEDVi's terms and conditions on its home storefront; MEDVi's privacy policy on its home storefront.

S7PASSIn a summer sale, the compounded semaglutide program costs $179 for the first month, with the physician review, plan and medication included, and refills are locked in at $299 a month. Compounded GLP-1 dissolving tablets start at $249, and the Wegovy pill, Wegovy and Zepbound cost a $99 membership plus the medication.Source: MEDVi's GLP-1 storefront.

S8PASSFDA warning letter 721455, February 2026, names MEDVi, LLC doing business as MEDVi at the Newark, Delaware street address this seller prints. It reviewed another website of the brand and says pictured labels named MEDVi as the compounder and that claims of the same active ingredient as Wegovy, Ozempic, Mounjaro and Zepbound implied FDA approval. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded GLP-1 injections, compounded GLP-1 dissolving tablets, Wegovy pill, Wegovy, Zepbound.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 721455, issued February 2026, to MEDVi, LLC dba MEDViPictured labels identify MEDVi as the compounder of semaglutide and tirzepatide products when it is not, and claims of the same active ingredient as Wegovy, Ozempic, Mounjaro and Zepbound imply the compounded products have been FDA-approved when they have not.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit MEDVi

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.